Discoveries beyond BRCA1/2: Multigene testing in an Asian multi-ethnic cohort suspected of hereditary breast cancer syndrome in the real world

10.1371/journal.pone.0213746PLoS ONE143e021374

Inadequate family history assessment by oncologists is an important physician barrier to referral for hereditary breast cancer evaluation

10.1016/j.clon.2013.11.029Clinical Oncology263174-175CLIO

Clinical genetic testing outcome with multi-gene panel in Asian patients with multiple primary cancers

10.18632/oncotarget.25769Oncotarget95530649-3066

A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours

10.1186/s12885-020-07616-4BMC Cancer201111

Impact of deviation from guideline recommended treatment on breast cancer survival in Asia

10.1038/s41598-020-58007-5Scientific Reports101133

Limb hypothermia for preventing paclitaxel-induced peripheral neuropathy in breast cancer patients: A pilot study

10.3389/fonc.2016.00274Frontiers in Oncology6JAN27

Low Levels of NDRG1 in nerve tissue are predictive of severe paclitaxel-induced neuropathy

10.1371/journal.pone.0164319PLoS ONE1110e016431

Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer

10.18632/oncotarget.11596Oncotarget73964089-6409